Enlivex Therapeutics is trading 7.2% down today at $1.81 as the market continues to digest a highly dilutive, crypto-linked $400 million private placement announced earlier this week.
- The stock faces sustained selling pressure following a 47% plunge on July 28 and a subsequent 13% drop on July 30 after the deal was first disclosed.
- Today's decline suggests ongoing investor concern regarding the financing terms, effectively offsetting a brief reassessment bounce seen during pre-market trading.